Tag: Xofigo

NICE rejects Lilly’s Portrazza, but backs Bayer’s Xofigo and Amgen’s Imlygic

by Selina McKee | Sep 30, 2016 | News | 0

Cost regulators for the NHS in England and Wales have published final guidelines turning down the use of Eli Lilly’s Portrazza to treat lung cancer, but backing Bayer’s Xofigo for prostate cancer and Amgen’s Imlygic for melanoma.

NICE widens scope of Bayer’s Xofigo

by Selina McKee | Sep 2, 2016 | News | 0

The National Institute for Health and Care Excellence has expanded the treatment scope of Bayer’s Xofigo so that prostate cancer patients not suitable for chemotherapy can now also access the therapy on the NHS.